Hi ,

• There Is No Problem Biology Can't Solve…Except For Economics. For biomanufacturing to reach its full potential, we have to build infrastructure, which must be cheap. Although many brilliant minds and companies are cooking up new ways to brew bioproducts, comparatively few are working on solving the infrastructure and scale-up problem.

• Biological Materials Enter the Solid-State Era. Scientists have pioneered a new technique for preserving biological materials like RNA and proteins in a solid-state, akin to a pill or tablet.
  

• Rubi and Walmart Collab Looks to Weave a Greener Future with Carbon Capture Technology. Walmart, the world's largest omnichannel retailer, has teamed up with Rubi, a pioneer in sustainable manufacturing, to pilot a series of projects to transform carbon emissions into textiles.

• Single-Cell Sequencing Gets a Serious Boost from Engineered Polymerase. In a groundbreaking development that could revolutionize single-cell research, scientists have devised a method to significantly reduce bias in the gene amplification stage of single bacterial cell genome sequencing.

• Visualizing How Microbes Turn CO2 into Bioplastic: In recent years, scientists have engineered microbe-semiconductor biohybrids, a fusion of the biosynthetic capabilities of living systems with the light-harvesting prowess of semiconductors.

• Photosynthesis Reimagined: In-Cell Engineering Yields Remarkable Hybrid Catalysts. Researchers have harnessed the power of in-cell engineering to create hybrid solid catalysts with exceptional catalytic properties.

• Synthetic Peptide Could Turn the Tide in the Fight Against Antibiotic-Resistant Bacteria. Scientists have engineered a short peptide that can neutralize a critical enzyme in harmful bacteria. This discovery could pave the way for new treatments to combat the growing threat of antibiotic resistance.

• Taming the T Cells: A Revolutionary Step in CAR T-Cell Therapy. A promising technique known as CAR T-cell therapy has been making waves in immunotherapy. This method has been approved for the fight against lymphoma and leukemia.

• Protein Nano-Switches: Building Better Diagnostics for the Future: Researchers have devised a cutting-edge approach to designing molecular ON-OFF switches based on proteins, with vast implications for biotechnology.
  

• Unraveling Space Health with Bioprinted Hearts. Over the course of five years, the PULSE project aims to drive technological innovations that will improve human health and pave the way for safer and more sustainable space exploration endeavors.

• The Bioaction Project’s Innovative Fight Against Antimicrobial Resistance. Instead of directly battling pathogenic bacteria, Bioaction harnesses them as beneficial partners to foster tissue regeneration and improve implant integration.

• The Butterfly Biomaterial Effect: Using Chitin to Shape the Future of Engineering and Biomedicine. Scientists have unlocked the potential of chitin, an organic polymer, for engineering and biomedical applications.

Other news:

• bitBiome Closes USD 2.8 M in Oversubscribed Series B2 Round First Close Funding. The funds raised will be used to strengthen the platform technologies for internal research and development projects, including the development of proprietary enzymes to address environmental or healthcare issues. (Press release)

• Fifty Years Manifest Grants is a fast grants program that awards $25K - $100K to scientists to accelerate their most ambitious ideas to solve the world’s biggest problems.

• Research Ventures Catalyst: open for applications. A pilot program in the UK that will stimulate the creation of novel research ventures via entrepreneurial team-based approaches in collaboration with partners drawn from the public sector, industry, and the third sector.

• FDA's Peter Marks says gene editing breakthroughs have met regulatory reality: Marks thinks gene editing—specifically base editing—could be a "game changer," but progress has been slow, likely due to discouragement with the regulatory process. (FierceBiotech)

• Conagen and Sumitomo Chemical will jointly develop p-hydroxystyrene (HS) and its polymer, poly p-hydroxystyrene (PHS), using a combination of biosynthesis, chemosynthesis and polymerization. (Press release)

  
  

Regards,
Jeff

---

Jeff Buguliskis, PhD 

Director of Content, SynBioBeta

Who's hiring?

• Sales Associate at SynBioBeta (Remote)

• Senior Scientific Implementation Manager at Ganymede (Remote)

• Senior Scientific Software Engineer at Ganymede (Remote)

• Software Engineer (Full-stack) at Ganymede (Remote)

• Business Development Associate at Ganymede (Remote)

• Outbound Sales Development at LatchBio (San Francisco, CA)

• Various Positions at Absci

• Various Positions at National Security Commission on Emerging Biotechnology